Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
Ligand's Technologies Support and Enable Potential Coronavirus Treatments
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th
Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
Ligand Reports Third Quarter 2019 Financial Results
Ligand to Report Third Quarter 2019 Results on November 5th
